Literature DB >> 20497385

Metabolic abnormalities in adults with cystic fibrosis.

Vasiliki V Georgiopoulou1, Adam Denker, Kathy L Bishop, Jason M Brown, Benjamin Hirsh, Linda Wolfenden, Laurence Sperling.   

Abstract

BACKGROUND AND
OBJECTIVE: Survival of patients with cystic fibrosis (CF) has improved, resulting in increased exposure of patients to cardiovascular risk factors. Diabetes mellitus is common in patients with CF; however, less is known about lipid abnormalities in this population. In this study, the prevalence of lipid abnormalities was investigated in a contemporary population of adults with CF.
METHODS: Clinical and laboratory data on 221 adult patients with CF were collected retrospectively. Fasting serum glucose levels and lipid profiles were recorded. The age-specific values for healthy individuals, as reported by the National Health and Nutrition Examination Surveys, were used for comparison.
RESULTS: The mean age of the patients was 30 +/- 10 years, 55.1% were men and the mean FEV(1)% was 68 +/- 25%. Sixty-nine patients (31.2%) had CF-related diabetes mellitus and 52 (23.5%) were receiving insulin therapy. In addition, 36 patients (16.3%) had impaired glucose tolerance. Triglyceride levels were similar to those of historical control subjects (mean +/- SEM, 1.37 +/- 0.05 and 1.39 +/- 0.02 mmol/L, respectively, P = 0.75). However, in the 30-39 years age group of CF patients, triglyceride levels were increased relative to those of their control counterparts (1.79 +/- 0.14 vs 1.38 +/- 0.04 mmol/L, P = 0.006). Total cholesterol levels were lower in the CF patients compared with control subjects, across all age groups.
CONCLUSIONS: Abnormalities of glucose metabolism are highly prevalent in CF patients, and are accompanied by hypertriglyceridaemia in the 30-39 years age group. Prospective studies are required to confirm lipid abnormalities and investigate possible cardiovascular complications in patients with CF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497385     DOI: 10.1111/j.1440-1843.2010.01771.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

Review 1.  Hepatic Manifestations of Cystic Fibrosis.

Authors:  Sasan Sakiani; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Clin Liver Dis       Date:  2019-02-21       Impact factor: 6.126

2.  Metabonomics reveals altered metabolites related to inflammation and energy utilization at recovery of cystic fibrosis lung exacerbation.

Authors:  Marianne S Muhlebach; Wei Sha; Beth MacIntosh; Thomas J Kelley; Joseph Muenzer
Journal:  Metabol Open       Date:  2019-06-08

3.  Modulation of the lipidomic profile due to a lipid challenge and fitness level: a postprandial study.

Authors:  Ciara Morris; Colm M O'Grada; Miriam F Ryan; Michael J Gibney; Helen M Roche; Eileen R Gibney; Lorraine Brennan
Journal:  Lipids Health Dis       Date:  2015-07-01       Impact factor: 3.876

4.  Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis.

Authors:  Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Krzysztof Dziedzic; Aleksandra Lisowska; Szymon Kurek; Joanna Goździk-Spychalska; Victoria Kononets; Dagmara Woźniak; Edyta Mądry; Jarosław Walkowiak
Journal:  Biomolecules       Date:  2021-02-19

Review 5.  Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data.

Authors:  Pieter-Jan De Sutter; Maxime Van Haeverbeke; Eva Van Braeckel; Stephanie Van Biervliet; Jan Van Bocxlaer; An Vermeulen; Elke Gasthuys
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-29

Review 6.  The Changing Landscape of Nutrition in Cystic Fibrosis: The Emergence of Overweight and Obesity.

Authors:  Julianna Bailey; Stefanie Krick; Kevin R Fontaine
Journal:  Nutrients       Date:  2022-03-13       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.